Company Overview of Intellikine LLC
Intellikine LLC discovers and develops small molecule drugs that target signal transduction networks for the treatment of cancer, inflammation, and autoimmune disorders. The company products include INK128, an orally-available TORC1/2 inhibitor for the treatment of solid tumor malignancies; INK1197, a small molecule dual PI3K selective inhibitor for patients with immune-mediated inflammatory diseases, such as rheumatoid arthritis and asthma; and PI3K selective inhibitors for the treatment of hematologic malignancies and solid tumors. The company was founded in 2007 and is based in La Jolla, California. Intellikine LLC operates as a subsidiary of Millennium Pharmaceuticals, Inc.
10931 North Torrey Pines Road
La Jolla, CA 92037-1044
Founded in 2007
Key Executives for Intellikine LLC
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Intellikine LLC, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.